Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences, Inc. (CRBU) is a healthcare company (biotechnology) based in the United States. The share price is $0.34, down 4.79% on the day, which values the company at $36.29M. Price as of 17 Nov 2026, 19:06 UTC, from Yahoo Finance.

Key facts

Share price
$0.34−4.79% today
Market value
$36.29M
Funk Score
28/100
Against its own history
Well below its usual priceusual price $1.60
200-week average
$2.9489% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Caribou Biosciences, Inc. in more detail

CRBU trades at -0.5× next year's expected earnings, 3.8× sales. Measured against its own history, the price is 79% below what its usual multiples would imply ($1.60) — well below its usual price. It sits 89% below its 200-week average of $2.94.

Over the last five fiscal years Caribou Biosciences, Inc. has compounded revenue -2.0% a year. Its Funk Score is 28 out of 100 (financial strength 4.2, profitability 0.0, growth 2.1, value 5.0, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

1 of the superinvestors tracked here hold CRBU, including Lee Ainslie (0.0% of the portfolio).

Superinvestors holding CRBU

1 of the investors tracked here report a position in their latest 13F filing.

Caribou Biosciences, Inc. (CRBU): questions and answers

What is Caribou Biosciences, Inc.'s market cap?

Caribou Biosciences, Inc. is valued at $36.29M at a share price of $0.34.

Is CRBU overvalued or undervalued?

Against its own history, CRBU is well below its usual price: the price is 79% below the $1.60 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is CRBU above its 200-week moving average?

No. CRBU is 88.6% below its 200-week average of $2.94. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Caribou Biosciences, Inc. growing?

Over the last five fiscal years Caribou Biosciences, Inc.'s revenue grew -2.0% a year.

Does CRBU pay a dividend?

Caribou Biosciences, Inc. does not currently pay a regular dividend.

Which famous investors own CRBU?

In their latest quarterly filings, Lee Ainslie (0.0% of the portfolio) hold CRBU. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Caribou Biosciences, Inc. (CRBU) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CRBU

Underlying data: Yahoo Finance; company filings with the SEC.